Literature DB >> 9257774

In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.

M Del Poeta1, W A Schell, J R Perfect.   

Abstract

The in vitro activity of the new antifungal drug pneumocandin L-743,872 against 55 isolates of clinically important molds was examined by an adapted macrobroth dilution method for yeasts. Pneumocandin L-743,872 exhibited in vitro antifungal activity against Alternaria sp., Aspergillus flavus, Aspergillus fumigatus, Curvularia lunata, Exophiala jeanselmei, Fonsecaea pedrosoi, Paecilomyces variotii, and Scedosporium apiospermum. The drug appeared to lack significant in vitro inhibitory activity against Fusarium oxysporum, Fusarium solani, Rhizopus arrhizus, Paecilomyces lilacinus, and Scedosporium prolificans.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9257774      PMCID： PMC164018     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  2 in total

1.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi.

Authors:  I Pujol; J Guarro; C Llop; L Soler; J Fernández-Ballart
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

Authors:  A Espinel-Ingroff; K Dawson; M Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; V Paetznick; J Peter; M Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191
  2 in total
  44 in total

1.  Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model.

Authors:  G M González; R Tijerina; L K Najvar; R Bocanegra; M Luther; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates.

Authors:  Sevtap Arikan; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

3.  What's New in Antifungals?

Authors:  John M. Valgus
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

4.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 5.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

6.  In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.

Authors:  J Meletiadis; J W Mouton; J L Rodriguez-Tudela; J F Meis; P E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

7.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 8.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 9.  Management and Novel Adjuncts of Necrotizing Soft Tissue Infections.

Authors:  Christine S Cocanour; Phillip Chang; Jared M Huston; Charles A Adams; Jose J Diaz; Charles B Wessel; Bonnie A Falcione; Graciela M Bauza; Raquel A Forsythe; Matthew R Rosengart
Journal:  Surg Infect (Larchmt)       Date:  2017-04-04       Impact factor: 2.150

Review 10.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.